Founded in 2014, Bionova offers world-class biologics CDMO services built on a foundation of strong process development and analytical science with a staff that brings decades of experience in late stage and commercial launch projects. We firmly believe that a robust, well-understood process and well-characterized molecule are critical cornerstones of your molecule’s success. Our upstream PD group, with more than 60 benchtop bioreactors, offers a breadth and depth of capability typically found at only the largest CDMO’s. Bionova takes an expansive view at solving client process problems. In 2021, Bionova opened a, 11,000 sq. ft. GMP biologics manufacturing facility to provide clinical and commercial production for clients. The fully single-use facility is located within Bionova’s 57,000 sq. ft. headquarters, adjacent to existing process development and analytical laboratories, and is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins.